Cardio-Thoracic-Vascular Department, San Raffaele Hospital, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
Interact Cardiovasc Thorac Surg. 2021 Apr 8;32(3):380-385. doi: 10.1093/icvts/ivaa270.
Among patients undergoing transcatheter mitral valve repair with the MitraClip device, a relevant proportion (2-6%) requires open mitral valve surgery within 1 year after unsuccessful clip implantation. The goal of this review is to pool data from different reports to provide a comprehensive overview of mitral valve surgery outcomes after the MitraClip procedure and estimate in-hospital and follow-up mortality.
All published clinical studies reporting on surgical intervention for a failed MitraClip procedure were evaluated for inclusion in this meta-analysis. The primary study outcome was in-hospital mortality. Secondary outcomes were in-hospital adverse events and follow-up mortality. Pooled estimate rates and 95% confidence intervals (CIs) of study outcomes were calculated using a DerSimionian-Laird binary random-effects model. To assess heterogeneity across studies, we used the Cochrane Q statistic to compute I2 values.
Overall, 20 reports were included, comprising 172 patients. Mean age was 70.5 years (95% CI 67.2-73.7 years). The underlying mitral valve disease was functional mitral regurgitation in 50% and degenerative mitral regurgitation in 49% of cases. The indication for surgery was persistent or recurrent mitral regurgitation (grade >2) in 93% of patients, whereas 6% of patients presented with mitral stenosis. At the time of the operation, 80% of patients presented in New York Heart Association functional class III-IV. Despite favourable intraoperative results, in-hospital mortality was 15%. The rate of periprocedural cerebrovascular accidents was 6%. At a mean follow-up of 12 months, all-cause death was 26.5%. Mitral valve replacement was most commonly required because the possibility of valve repair was jeopardized, likely due to severe valve injury after clip implantation.
Surgical intervention after failed transcatheter mitral valve intervention is burdened by high in-hospital and 1-year mortality, which reflects reflecting the high-risk baseline profile of the patients. Mitral valve replacement is usually required due to leaflet injury.
在接受 MitraClip 装置经导管二尖瓣修复的患者中,有相当一部分(2-6%)在夹闭植入不成功后 1 年内需要行二尖瓣切开术。本综述的目的是汇总来自不同报告的数据,提供经导管二尖瓣修复术后行二尖瓣手术结果的全面概述,并估计住院期间和随访死亡率。
评估了所有发表的报告经导管二尖瓣修复术失败后行手术干预的临床研究,以纳入本荟萃分析。主要研究结局为住院期间死亡率。次要结局为住院期间不良事件和随访死亡率。使用 DerSimionian-Laird 二项随机效应模型计算研究结局的汇总估计率和 95%置信区间(CI)。为评估研究间的异质性,我们使用 Cochrane Q 统计量计算了 I2 值。
共有 20 项研究报告纳入,共纳入 172 例患者。平均年龄为 70.5 岁(95%CI 67.2-73.7 岁)。基础二尖瓣疾病为功能性二尖瓣反流占 50%,退行性二尖瓣反流占 49%。手术指征为持续性或复发性二尖瓣反流(分级>2)占 93%的患者,而 6%的患者存在二尖瓣狭窄。手术时,80%的患者处于纽约心脏协会功能分级 III-IV 级。尽管术中结果良好,但住院期间死亡率仍为 15%。围手术期脑血管意外发生率为 6%。平均随访 12 个月时,全因死亡率为 26.5%。最常需要行二尖瓣置换术,因为瓣叶修复的可能性受到威胁,可能是由于夹闭植入后瓣叶严重损伤。
经导管二尖瓣介入治疗失败后行手术干预,住院期间和 1 年死亡率较高,反映了患者的高危基线特征。由于瓣叶损伤,通常需要行二尖瓣置换术。